First patient dosed in trial aiming to reprogram cells

partial reprogramming – Life Biosciences says it has dosed the first participant in a gene-therapy trial designed to “partially reprogram” aged cells by activating three genes. The treatment is being tested for glaucoma, with the safety strategy built around turning gene activity on

The first patient has been treated in a highly anticipated gene therapy trial that is trying to coax aged cells into taking on a younger identity.

Life Biosciences. a company based in Boston. Massachusetts. announced on 9 June that it had dosed its first participant in the study. The clinical trial is built around a novel approach: turning on three genes that. scientists say. can “partially reprogram” old cells. The company is not pursuing this as a general anti-ageing intervention. It is testing the idea as a disease treatment—specifically for glaucoma, a condition that can cause blindness.

The hope is that turning on those genes will allow regeneration of neurons in the optic nerve. Those neurons connect the eye to the brain, and in people with glaucoma they can be damaged. The challenge is that these neurons do not normally regenerate in adults.

Gene therapy is often discussed as a hopeful frontier. but this trial arrives with a sharper kind of tension: partial reprogramming could potentially rejuvenate old organs. yet the safety question is hard to ignore. Some scientists have pointed to animal studies in several labs suggesting that partial reprogramming can be done safely. Still. there is a fear that the process could tip some cells into a cancerous state—an outcome that would transform a medical breakthrough into a warning.

Matt Kaeberlein. co-founder of Optispan. a longevity-focused preventative medicine company in Seattle. Washington. framed the promise and peril in the same breath. “Reprogramming has a big upside if it can be used safely in people,” he said. “The technology is still really early, and the potential for catastrophic side effects is high.”.

For Kaeberlein, the eye is a practical place to start. “The eye is likely a good first place to try the technique,” he said, because the chances of life-threatening side effects are lower with changes to the eye than to some other organs.

Life Biosciences is relying on a virus commonly used in gene therapy to deliver the three reprogramming genes into retinal ganglion cells. Those cells are crucial because their long arms make up the optic nerve. The company also built an added safety control into the design: the system is engineered so the genes are switched on when the participant takes an antibiotic called doxycycline. If the antibiotic is withdrawn, the genes switch off.

Sharon Rosenzweig-Lipson, chief scientific officer at the company, described the value of that toggle. “It gives us a lot of control,” she said. “And the ability not just to turn it on, but to turn it off and not leave on expression longer than is necessary to rejuvenate the cells.”

The scientific work behind the trial draws on earlier findings. In 2020. researchers in David Sinclair’s lab at Harvard Medical School in Boston. Massachusetts. and colleagues reported that activating these three genes in mice with damaged optic nerves promoted neuron regeneration and reversed vision loss in aged mice and mice with glaucoma.

Since then, Life Biosciences says it has studied the approach in rodents and monkeys and “has not seen serious adverse effects of the treatment,” according to Rosenzweig-Lipson.

In the clinical trial, the company aims to treat as many as 12 people with glaucoma. It also plans to eventually include participants with a severe, acute condition called NAION, which also causes nerve damage in the eye.

A key question now is what “rejuvenation” means in real human terms. Pete Williams. a translational neurobiologist at the Centre for Eye Research Australia in Melbourne. welcomed the trial’s fresh strategy for treating retinal nerve damage. But he cautioned that the broader promise—whether the modified cells are truly “younger” and can enhance longevity—still sits beyond what the current study can prove.

Williams also worries about another force: attention. “If this goes catastrophically wrong, it might screw us all in the future,” he said. “It’s gotten a lot of hype.”

Rosenzweig-Lipson, for her part, says the company is moving carefully, step by step. She said Life Biosciences is proceeding “one age-related disease at a time.” “We’re not looking at whole-body rejuvenation at this point in time. ” she said. “We hope to get there someday. but we’re not there now.” The company has also been studying its approach in animal models of liver disease.

For now, the trial’s immediate goal is narrower and stark: to test the safety of the reprogramming approach. That focus reflects the field’s lingering concern—because while partial reprogramming may offer a path to reversing damage, it also has a built-in risk profile that cannot be assumed away.

The company’s first dosing. announced on 9 June. marks a turning point for a strategy that has been largely studied in animals. Whether it can deliver on the promise for glaucoma—without crossing the line into dangerous biology—will become the real measure of whether “turning back the clock” in the lab can ever work in the clinic.

This article is reproduced with permission and was first published on June 9, 2026.

gene therapy partial reprogramming glaucoma optic nerve neurons doxycycline Life Biosciences NAION retinal ganglion cells longevity medicine Matt Kaeberlein Sharon Rosenzweig-Lipson David Sinclair